Molecular Partners AG

AI Score

0

Unlock

5.38
-0.10 (-1.82%)
At close: Jan 14, 2025, 3:58 PM
5.36
-0.37%
After-hours Jan 14, 2025, 03:59 PM EST
undefined%
Bid 5.42
Market Cap 198.32M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.06
PE Ratio (ttm) -2.61
Forward PE n/a
Analyst Hold
Ask 6.19
Volume 5,938
Avg. Volume (20D) 24,862
Open 5.49
Previous Close 5.48
Day's Range 5.38 - 5.50
52-Week Range 3.32 - 12.70
Beta undefined

About MOLN

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for th...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2021
Employees 167
Stock Exchange NASDAQ
Ticker Symbol MOLN

Analyst Forecast

According to 1 analyst ratings, the average rating for MOLN stock is "Hold." The 12-month stock price forecast is $4.5, which is a decrease of -16.36% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
+14.18%
Molecular Partners shares are trading higher after... Unlock content with Pro Subscription
7 months ago · Source
+13.78%
Molecular Partners shares are trading higher after the comapny announced preclinical proof-of-concept data from MP0621.